Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Daniel B Landi"'
Autor:
Annick Desjardins, Vidyalakshmi Chandramohan, Daniel B Landi, Margaret O. Johnson, Mustafa Khasraw, Katherine B. Peters, Justin Low, James Emmett Herndon, Stevie Threatt, Chevelle A. Bullock, Eric S. Lipp, John H. Sampson, Allan H. Friedman, Henry S. Friedman, David M. Ashley, David Knorr, Darell D. Bigner
Publikováno v:
Journal of Clinical Oncology. 40:e14015-e14015
e14015 Background: D2C7 immunotoxin (D2C7-IT) is a dual-specific recombinant immunotoxin comprising an EGFR wild-type and mutant-specific (EGFRvIII) monoclonal antibody (Ab) fragment and a genetically engineered form of the Pseudomonas exotoxin. When
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::06f9bc8fb1091bcf4efa0245368847fb
https://doi.org/10.1200/jco.2022.40.16_suppl.e14015
https://doi.org/10.1200/jco.2022.40.16_suppl.e14015
Autor:
Daniel B Landi, David S. Ziegler, Andrea Flynn Franson, Patricia Ann Baxter, Sarah Leary, Valérie Larouche, Angela Jae Waanders, Jasper Van der Lugt, Geoffrey Brian McCowage, Francois Doz, Nada Jabado, Elisabetta Schiavello, Michal Zapotocky, Izzy Cornelio, Samuel C Blackman, Daniel Da Costa, Michael Craig Cox, Olaf Witt, Lindsay Baker Kilburn, Jordan R. Hansford
Publikováno v:
Journal of Clinical Oncology. 40:TPS10062-TPS10062
TPS10062 Background: RAF gene fusions ( BRAF and RAF1) and BRAF V600E mutations are oncogenic drivers found on a mutually exclusive basis in most pediatric low-grade gliomas (LGGs). In addition, RAF fusions ( BRAF and RAF1) have also been identified
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::94e008124ee3150bd43a94227604f46d
https://doi.org/10.1200/jco.2022.40.16_suppl.tps10062
https://doi.org/10.1200/jco.2022.40.16_suppl.tps10062
Autor:
Jaap Jan Boelens, Mieke Aldenhoven, Duncan Purtill, Annalisa Ruggeri, Todd DeFor, Robert Wynn, Ed Wraith, Marina Cavazzana-Calvo, Attilio Rovelli, Alain Fischer, Jakub Tolar, Vinod K. Prasad, Maria Escolar, Eliane Gluckman, Anne O’Meara, Paul J. Orchard, Paul Veys, Mary Eapen, Joanne Kurtzberg, Vanderson Rocha, Timothy A. Driscoll, Daniel B. Landi, Paul L. Martin, Kristin M. Page, Suhag H Parikh
We report transplantation outcomes of 258 children with Hurler syndrome (HS) after a myeloablative conditioning regimen from 1995 to 2007. Median age at transplant was 16.7 months and median follow-up was 57 months. The cumulative incidence of neutro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::815de4a32bcd07b1e20a2a1719c476fe
https://europepmc.org/articles/PMC3836041/
https://europepmc.org/articles/PMC3836041/
